20 results on '"Kuempers C"'
Search Results
2. PL03.07 Invasion or No Invasion, That’s the Question. A Large Reproducibility Study in Pulmonary Adenocarcinoma, Supporting a Modified Classification
- Author
-
Thunnissen, E., primary, Blaauwgeers, H., additional, Filipello, F., additional, Lissenberg-Witte, B., additional, Minami, Y., additional, Noguchi, M., additional, Le Quense, J., additional, Papotti, M.G., additional, Flieder, D., additional, Pelosi, G., additional, Sansano, I., additional, Berezowska, S., additional, Ryška, A., additional, Brcic, L., additional, Motoi, N., additional, Nakatani, Y., additional, Kuempers, C., additional, Hofman, P., additional, Hofman, V., additional, Grotnes Dale, V., additional, Rossi, G., additional, Ambrosi, F., additional, Matsubara, D., additional, Ishikawa, Y., additional, Weynand, B., additional, Calabrese, F., additional, Pezzuto, F., additional, Kern, I., additional, Nicholson, S., additional, Mutka, A.-L., additional, Dacic, S., additional, Beasley, M.B., additional, Arrigoni, G., additional, Timens, W., additional, Ooft, M., additional, Brinkhuis, M., additional, Bulkmans, N., additional, Britstra, R., additional, Vreuls, W., additional, Jones, K., additional, von der Thüsen, J., additional, Hager, H., additional, Perner, S., additional, Moore, D., additional, Leonte, D.G., additional, Al-Janabi, S., additional, Schønau, A., additional, Stenzinger, A., additional, and Kazdal, D., additional
- Published
- 2023
- Full Text
- View/download PDF
3. 1200P Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
- Author
-
Homs Soler, M., Kren, J., Bonsanto, M.M., Honselmann, K.C., Keck, T., Hemptenmacher, F., Banys- Paluchowski, M., Rody, A., Roesch, M., Merseburger, A.S., Ha-Wissel, M.L., Gaffal, E., Hundt, J., Rose, C., Neumann, J.E., Berg, N., Kümpers, C., Sailer, V-W., Oberländer, M., and Brinkmann, R.
- Published
- 2024
- Full Text
- View/download PDF
4. Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients
- Author
-
Kuempers, C., primary, van der Linde, L. I. S., additional, Reischl, M., additional, Vogel, W., additional, Stellmacher, F., additional, Reck, M., additional, Heigener, D., additional, Rabe, K. F., additional, Kirfel, J., additional, Perner, S., additional, and Welker, L., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Prognostic value of the new prostate cancer grading system
- Author
-
Offermann, A., primary, Kuempers, C., additional, Ribbat-Idel, J., additional, Becker, F., additional, Hohensteiner, S., additional, Schneider, F., additional, Hupe, M.C., additional, Merseburger, A., additional, Lubczyk, V., additional, Kuefer, R., additional, and Perner, S., additional
- Published
- 2018
- Full Text
- View/download PDF
6. 217 - Prognostic value of the new prostate cancer grading system
- Author
-
Offermann, A., Kuempers, C., Ribbat-Idel, J., Becker, F., Hohensteiner, S., Schneider, F., Hupe, M.C., Merseburger, A., Lubczyk, V., Kuefer, R., and Perner, S.
- Published
- 2018
- Full Text
- View/download PDF
7. A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers.
- Author
-
Thunnissen E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, Minami Y, Noguchi M, Quesne JL, Papotti MG, Flieder DB, Pelosi G, Sansano I, Berezowska S, Ryška A, Brcic L, Motoi N, Nakatani Y, Kuempers C, Hofman P, Hofman V, Dale VG, Rossi G, Ambrosi F, Matsubara D, Ishikawa Y, Weynand B, Calabrese F, Pezzuto F, Kern I, Nicholson S, Mutka A, Dacic S, Beasley MB, Arrigoni G, Timens W, Ooft M, Brinkhuis M, Bulkmans N, Britstra R, Vreuls W, Jones KD, von der Thüsen JH, Hager H, Perner S, Moore D, Leonte DG, Al-Janabi S, Schønau A, Neumann O, Kluck K, Ourailidis I, Ball M, Budczies J, Kazdal D, and Stenzinger A
- Abstract
Objectives: Evaluating invasion in non-mucinous adenocarcinoma (NMA) of the lung is crucial for accurate pT-staging. This study compares the World Health Organization (WHO) with a recently modified NMA classification., Materials and Methods: A retrospective case-control study was conducted on small NMA pT1N0M0 cases with a 5-year follow-up. Seventy cases were reviewed by 42 pulmonary pathologists first according to the WHO classification and after tutorial according to a modified classification. A third round was conducted based on feedback from 41 peers of previous rounds. Additionally, orthogonal biomarker analysis was performed., Results: In the first two rounds, 42 pathologists from 13 countries assessed all 70 cases, while 36 pathologists evaluated 41 non-unanimous cases in the third round. Kappa values for invasiveness increased in rounds 1, 2, and 3 to 0.27, 0.45 and 0.62, respectively. In contrast to low variation in total tumor size measurements (6 %), a marked increase in invasive tumor size variation was observed (42 %), which was associated with high uncertainty. In the third round 10 cases were non-invasive, all without recurrence. The modified classification showed in the 3rd round marked reduction of the variation in pT staging compared to the current WHO classification. Proliferation rate, tumor mutational burden, and transcriptomic profiles supported the distinction between invasive cases and non-invasive cases of the modified classification., Conclusion: The modified classification demonstrates essentially higher reproducibility compared to the current WHO classification in NMA. The modified classification proves valuable in identifying low-risk lesions that are entirely non-invasive, and is supported by biomarker analysis., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Upregulation and epigenetic modification of the creatine transporter SLC6A8 in non-small cell lung cancer.
- Author
-
Kuempers C, Schnepf K, Marwitz S, Watermann C, Scheel AH, Fischer RN, Ammerpohl O, Perner S, Drömann D, and Goldmann T
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Gene Expression Regulation, Neoplastic, Plasma Membrane Neurotransmitter Transport Proteins genetics, Plasma Membrane Neurotransmitter Transport Proteins metabolism, Prognosis, Kaplan-Meier Estimate, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Nerve Tissue Proteins genetics, Nerve Tissue Proteins metabolism, Adult, Membrane Transport Proteins, Lung Neoplasms genetics, Lung Neoplasms pathology, Lung Neoplasms metabolism, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Epigenesis, Genetic, Up-Regulation
- Abstract
Introduction: Lung cancer is a major cause of cancer-related death worldwide and effective therapies, besides surgery, are available only for a small proportion of patients. Since cellular respiration is known to be broadly altered in malignant tumors, the cellular processes of respiration can be a potential therapeutic target. One important element of cellular respiration is creatine and its transport by the creatine transporter SLC6A8. Here we describe the expression of SLC6A8 at the RNA and protein level, epigenetic modifications as well as survival analysis in NSCLC tissues and matched controls., Materials and Methods: We analyzed epigenetic modifications of the SLC68A gene in 32 patients, of which 18 were additionally analyzed by transcriptome analysis. The expression of SLC6A8 at the protein level was assessed by immunohistochemistry using an independent cohort and correlated with clinicopathological data including survival. Kaplan-Meier analysis was performed to analyze the possible effects of the transcriptional levels of SLC6A8 in another separate cohort (n=1925)., Results: SLC6A8 loci are epigenetically modified in NSCLC compared with tumor-free controls. SLC6A8 is upregulated in NSCLC at the RNA and protein level. High mRNA expression of SLC6A8 was associated with an overall poor prognosis in lung adenocarcinoma patients and displayed the strongest adverse prognostic effect in male smokers with adenocarcinomas. Results of transcriptome analysis were partially confirmed at the protein level., Conclusions: Our results suggest an important role of creatine and its transport via SLC6A8 in NSCLC., (©The Author(s) 2024. Open Access. This article is licensed under a Creative Commons CC-BY International License.)
- Published
- 2024
- Full Text
- View/download PDF
9. TRIM11 expression in non-small cell lung cancer is associated with poor prognosis.
- Author
-
Kuempers C, Jagomast T, Paulsen FO, Heidel C, Bohnet S, Schierholz S, Reischl M, Dreyer E, Olchers T, Reck M, Kirfel J, and Perner S
- Subjects
- Humans, Ubiquitin-Protein Ligases metabolism, Prognosis, Tripartite Motif Proteins metabolism, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms metabolism, Adenocarcinoma, Carcinoma, Squamous Cell
- Abstract
Background: Despite promising results of targeted therapy approaches, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death. Tripartite motif containing 11 (TRIM11) is part of the TRIM family of proteins, playing crucial roles in tumor progression. TRIM11 serves as an oncogene in various cancer types and has been reported to be associated with a poor prognosis. In this study, we aimed to investigate the protein expression of TRIM11 in a large NSCLC cohort and to correlate its expression with comprehensive clinico-pathological data., Methods: Immunohistochemical staining of TRIM11 was performed on a European cohort of NSCLC patients (n=275) including 224 adenocarcinomas and 51 squamous cell carcinomas. Protein expression was categorized according to staining intensity as absent, low, moderate and high. To dichotomize samples, absent and low expression was defined as weak and moderate and high expression was defined as high. Results were correlated with clinico-pathological data., Results: TRIM11 was significantly more highly expressed in NSCLC than in normal lung tissue and significantly more highly expressed in squamous cell carcinomas than in adenocarcinomas. We found a significantly worse 5-year overall survival for patients who highly expressed TRIM11 in NSCLC., Conclusions: High TRIM11 expression is linked with a poor prognosis and might serve as a promising novel prognostic biomarker for NSCLC. Its assessment could be implemented in future routine diagnostic workup., (©The Author(s) 2024. Open Access. This article is licensed under a Creative Commons CC-BY International License.)
- Published
- 2024
- Full Text
- View/download PDF
10. High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer.
- Author
-
Salcher S, Sturm G, Horvath L, Untergasser G, Kuempers C, Fotakis G, Panizzolo E, Martowicz A, Trebo M, Pall G, Gamerith G, Sykora M, Augustin F, Schmitz K, Finotello F, Rieder D, Perner S, Sopper S, Wolf D, Pircher A, and Trajanoski Z
- Subjects
- Humans, Neutrophils metabolism, Tumor Microenvironment, B7-H1 Antigen metabolism, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology
- Abstract
Non-small cell lung cancer (NSCLC) is characterized by molecular heterogeneity with diverse immune cell infiltration patterns, which has been linked to therapy sensitivity and resistance. However, full understanding of how immune cell phenotypes vary across different patient subgroups is lacking. Here, we dissect the NSCLC tumor microenvironment at high resolution by integrating 1,283,972 single cells from 556 samples and 318 patients across 29 datasets, including our dataset capturing cells with low mRNA content. We stratify patients into immune-deserted, B cell, T cell, and myeloid cell subtypes. Using bulk samples with genomic and clinical information, we identify cellular components associated with tumor histology and genotypes. We then focus on the analysis of tissue-resident neutrophils (TRNs) and uncover distinct subpopulations that acquire new functional properties in the tissue microenvironment, providing evidence for the plasticity of TRNs. Finally, we show that a TRN-derived gene signature is associated with anti-programmed cell death ligand 1 (PD-L1) treatment failure., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. CDK7 is a prognostic biomarker for non-small cell lung cancer.
- Author
-
Kuempers C, Jagomast T, Heidel C, Paulsen FO, Bohnet S, Schierholz S, Dreyer E, Kirfel J, and Perner S
- Abstract
Aim: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death globally despite promising progress of personalized therapy approaches. Cyclin-dependent kinase 7 (CDK7) is a kinase involved in transcription, overexpressed in a broad spectrum of cancer types and found to be associated with an unfavourable prognosis. In this study, we aimed to investigate the protein expression of CDK7 in a large cohort of NSCLC incorporating adenocarcinomas (adNSCLC) and squamous cell carcinomas (sqNSCLC) and to correlate its expression with clinicopathological data., Methods: We performed immunohistochemical staining of CDK7 on our cohort of NSCLC including 258 adNSCLC and 101 sqNSCLC and measured protein expression via a semi-automated read out. According to the median value of CDK7 the cohort was stratified in a CDK7 high and low expressing group, respectively, and results were correlated with clinico-pathological data., Results: CDK7 was significantly higher expressed in sqNSCLC than in adNSCLC. In the group of sqNSCLC, CDK7 expression was significantly higher in sqNSCLC with lymph node metastases than in sqNSCLC with N0 stage. We found a significantly worse overall survival and disease-free survival for patients with CDK7 high expressing NSCLC., Conclusion: Since a high CDK7 expression seems to be linked with a poor prognosis it might serve as a promising novel prognostic biomarker and its assessment could be implied in future routine diagnostic workup of NSCLC samples. Considering that CDK7 inhibitors are currently tested in several trials for advanced solid malignancies, it may also be a new target for future anti-cancer therapy., Competing Interests: SP is a consultant of Ventana, Roche, Novartis, Astellar, Astrazeneca, Bristol-Myers Squibb, Merck Serono and MSD. JK is a consultant of Roche, AMGEN and BMS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The above-mentioned companies had no influence on the study design, acquisition of data, or writing of the manuscript., (Copyright © 2022 Kuempers, Jagomast, Heidel, Paulsen, Bohnet, Schierholz, Dreyer, Kirfel and Perner.)
- Published
- 2022
- Full Text
- View/download PDF
12. Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples.
- Author
-
Kuempers C, Jagomast T, Krupar R, Paulsen FO, Heidel C, Ribbat-Idel J, Idel C, Märkl B, Anlauf M, Berezowska S, Tiemann M, Bösmüller H, Fend F, Kalsdorf B, Bohnet S, Dreyer E, Sailer V, Kirfel J, and Perner S
- Abstract
Rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate directed against Delta-like protein 3 (DLL3), is under development for patients with small cell lung cancer (SCLC). DLL3 is expressed on the majority of SCLC samples. Because SCLC is rarely biopsied in the course of disease, data regarding DLL3 expression in relapses is not available. The aim of this study was to investigate the expression of DLL3 in chemorelapsed (but untreated with Rova-T) SCLC samples and compare the results with chemonaive counterparts. Two evaluation methods to assess DLL3 expression were explored. Additionally, we assessed if DLL3 expression of chemorelapsed and/or chemonaive samples has prognostic impact and if it correlates with other clinicopathological data. The study included 30 paired SCLC samples, which were stained with an anti DLL3 antibody. DLL3 expression was assessed using tumor proportion score (TPS) and H-score and was categorized as DLL3 low (TPS < 50%, H-score ≤ 150) and DLL3 high (TPS ≥ 50%, H-score > 150). Expression data were correlated with clinicopathological characteristics. Kaplan-Meier curves were used to illustrate overall survival (OS) depending on DLL3 expression in chemonaive and chemorelapsed samples, respectively, and depending on dynamics of expression during course of therapy. DLL3 was expressed in 86.6% chemonaive and 80% chemorelapsed SCLC samples without significant differences between the two groups. However, the extent of expression varied in a substantial proportion of pairs (36.6% with TPS, 43.3% with H-score), defined as a shift from low to high or high to low expression. TPS and H-score provided comparable results. There were no profound correlations with clinicopathological data. Survival analysis revealed a trend toward a more favorable OS in DLL low-expressing chemonaive SCLC ( p = 0.57) and, in turn, in DLL3 high-expressing chemorelapsed SCLC ( p = 0.42) as well as in SCLC demonstrating a shift from low to high expression ( p = 0.56) without being statistically significant. This is the first study to investigate DLL3 expression in a large cohort of rare paired chemonaive-chemorelapsed SCLC specimens. Comparative analysis revealed that DLL3 expression was not stable during the course of therapy, suggesting therapy-based alterations. Unlike in chemonaive samples, a high DLL3 expression in chemorelapsed samples indicated a trend for a more favorable prognosis. Our results highlight the importance to investigate DLL3 in latest chemorelapsed SCLC tumor tissue., Competing Interests: SP is a consultant of Ventana, Roche, Novartis, Astellar, Astrazeneca, Bristol-Myers Squibb, Merck Serono and MSD. JK is a consultant of Roche, Novartis, BMS and MSD. BM received an honorary from AbbVie for a one-time consulting activity. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Kuempers, Jagomast, Krupar, Paulsen, Heidel, Ribbat-Idel, Idel, Märkl, Anlauf, Berezowska, Tiemann, Bösmüller, Fend, Kalsdorf, Bohnet, Dreyer, Sailer, Kirfel and Perner.)
- Published
- 2021
- Full Text
- View/download PDF
13. Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas.
- Author
-
Pasternack H, Kuempers C, Deng M, Watermann I, Olchers T, Kuehnel M, Jonigk D, Kugler C, Stellmacher F, Goldmann T, Kirfel J, Ammerpohl O, Perner S, and Reck M
- Subjects
- Adenocarcinoma of Lung surgery, Biomarkers, Tumor genetics, DNA Methylation, Epigenome, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms surgery, Transcriptome, Adenocarcinoma of Lung genetics, Lung Neoplasms genetics, Neoplasm Recurrence, Local genetics
- Abstract
The only potentially curative treatment for lung adenocarcinoma patients remains complete resection of early-stage tumors. However, many patients develop recurrence and die of their disease despite curative surgery. Underlying mechanisms leading to establishment of systemic disease after complete resection are mostly unknown. We therefore aimed at identifying molecular signatures of resected lung adenocarcinomas associated with the risk of an early relapse. The study comprised 89 patients with totally resected stage IA-IIIA lung adenocarcinomas. Patients suffering from an early relapse within two years after surgery were compared to patients without a relapse in two years. Patients were clinically and molecular pathologically characterized. Tumor tissues were immunohistochemically analyzed for the expression of Ki67, CD45, CD4, CD8, PD1, PD-L1, PD-L2 and CD34, by Nanostring nCounter PanCancer Immune Profiling Panel as well as a comprehensive methylome profiling using the Infinium MethylationEPIC BeadChip. We detected differential DNA methylation patterns as well as significantly differentially expressed genes associated with an early relapse after complete resection. Especially, CD1A was identified as a potential biomarker, whose reduced expression is associated with an early relapse. These findings might help to develop biomarkers improving risk assessment and patient selection for adjuvant therapy as well as establish novel targeted therapeutic strategies.
- Published
- 2021
- Full Text
- View/download PDF
14. Confocal laser microscopy without fluorescent dye in minimal-invasive thoracic surgery: an ex-vivo pilot study in lung cancer.
- Author
-
Ellebrecht DB, Kuempers C, Perner S, Kugler C, and Kleemann M
- Subjects
- Adenocarcinoma pathology, Endoscopy methods, Humans, Lasers, Microscopy, Confocal methods, Minimally Invasive Surgical Procedures, Pilot Projects, Thoracic Surgery, Adenocarcinoma surgery, Carcinoma, Non-Small-Cell Lung pathology, Fluorescent Dyes chemistry, Lung Neoplasms physiopathology
- Abstract
Cancer will be the leading cause of death in a few decades. In line with minimal invasive lung cancer surgery, surgeons loose most of their tactile tissue information and need an additional tool of intraoperative tissue navigation during surgery. Confocal laser microscopy is a well-established method of tissue investigation. In this ex-vivo pilot study, we evaluated an endoscopic confocal laser microscope (eCLM) that does not need any fluorescent dye as a diagnostic tool in non-malignant and malignant pulmonary tissue and distal stapler resection margins, respectively. In seven cases, an eCLM was used for examining pulmonary tissue ex-vivo . Images of non-malignant and non-small cell lung cancer tissue and distal stapler resection margins were characterized in terms of specific signal-patterns. No fluorescent dye was used. Correlations to findings in conventional histology were systematically recorded and described. Healthy lung tissue showed hyperreflectoric alveolar walls with dark alveolar spaces. Hyperreflective nets indicated the tumor stroma; whereas the hyperreflective areas indicated the tumor cell clusters. Compared to adenocarcinoma tissue, tissue from squamous cell carcinoma showed more distinctive hyperreflective stroma nets. eCLM characteristics seen in non-malignant and malignant tissue were also visible in distal stapler resection margins and so therefore it was feasible to distinguish between healthy lung tissue and lung cancer. This pilot study shows that the assessment of pulmonary tissue with this eCLM for minimally invasive surgical approach without any fluorescent dye is feasible. It enables to differentiate between benign and malignant tissue in pulmonary specimen by easy to evaluate and reproducible parameters., (© 2020 Walter de Gruyter GmbH, Berlin/Boston.)
- Published
- 2020
- Full Text
- View/download PDF
15. TRIM24 as an independent prognostic biomarker for prostate cancer.
- Author
-
Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, and Perner S
- Subjects
- Cohort Studies, Humans, Male, Prognosis, Prostatic Neoplasms pathology, Biomarkers, Tumor metabolism, Carrier Proteins genetics, Immunohistochemistry methods, Prostatic Neoplasms genetics, Zinc Fingers genetics
- Abstract
Introduction: Simply applicable biomarkers for prostate cancer patients predicting the clinical course are urgently needed. Recently, TRIM24 has been identified to promote androgen receptor signaling and to correlate with an aggressive prostate cancer phenotype. Based on these data, we proofed TRIM24 as a prognostic biomarker for risk stratification., Materials and Methods: We performed TRIM24 immunohistochemistry on 2 independent cohorts including a total of 806 primary tumors, 26 locally advanced/recurrent tumors, 30 lymph node metastases, 30 distant metastases, and 129 benign prostatic samples from 497 patients as well as on 246 prostate needle biopsies. Expression data were correlated with clinic-pathological data including biochemical recurrence-free survival (bRFS) as endpoint., Results: Benign samples show no or low TRIM24 expression in 94%, while tumor tissues demonstrate significant higher levels. Strongest expression is observed in advanced and metastatic tumors. In multivariate analyses, TRIM24 up-regulation on radical prostatectomy specimens correlates with shorter bRFS independent of other prognostic parameters. 5-(10-) year bRFS rates for TRIM24 negative, low, medium and high expressing tumors are 93.1(93.1)%, 75.4(68.5)%, 54.9(47.5)% and 43.1(32.3)%, respectively. Of interest, tumors diagnosed as indolent disease, TRIM24 expression stratifies patients into specific risk groups. Increased TRIM24 expression associates with higher grade group, positive nodal status and extraprostatic tumor growth. TRIM24 assessment on prostate needle biopsies taken prior to treatment decision at time of initial diagnosis significantly correlates with recurrence after surgery., Conclusion: Using 2 large independent radical prostatectomy specimen cohorts, we found that TRIM24 expression predicts patients' risk to develop disease recurrence with high accuracy and independent from other established biomarkers. Further, this is the first study exploring TRIM24 expression on prostate needle biopsies which represents the clinically relevant tissue type on which biomarkers guide treatment decisions. Thus, we strongly suggest introducing TRIM24 evaluation in prostate needle biopsies in clinical routine as an inexpensive and simple immunohistochemical test., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
16. Confocal laser microscopy as novel approach for real-time and in-vivo tissue examination during minimal-invasive surgery in colon cancer.
- Author
-
Ellebrecht DB, Kuempers C, Horn M, Keck T, and Kleemann M
- Subjects
- Adenocarcinoma diagnostic imaging, Adenocarcinoma pathology, Adenocarcinoma secondary, Animals, Cell Line, Tumor, Colon pathology, Colon surgery, Colonic Neoplasms diagnostic imaging, Colonic Neoplasms pathology, Computer Systems, Humans, Laparotomy, Male, Neoplasm Transplantation, Peritoneal Neoplasms diagnostic imaging, Peritoneal Neoplasms secondary, Peritoneum pathology, Peritoneum surgery, Rats, Adenocarcinoma surgery, Colon diagnostic imaging, Colonic Neoplasms surgery, Intraoperative Care methods, Microscopy, Confocal methods, Minimally Invasive Surgical Procedures methods, Peritoneum diagnostic imaging
- Abstract
Background: Histological analysis of surgical specimen is the gold standard for cancer classification. In particular, frozen histological diagnosis of vague peritoneal spots or uncertain excision of tumors plays a crucial role in the decision to proceed with or abandon an operation. Confocal laser microscopy (CLM) enables in-vivo and real-time high-resolution tissue analysis. This method has already been used during endoscopic assessments analyzing transformation of esophageal or colon mucosa. We examined whether a CLM device enables to distinguish between non-malignant and malignant tissue in vivo and real time and enables to assign peritoneal carcinomatosis spots to their primary tumor. In addition, we investigated whether the newly developed CLM camera device causes any tissue damage., Methods: CC531 colon carcinoma cells were implanted on the serosa side of the colon and intraperitoneally in Wag/Rija rats via laparotomy. After 7 days of tumor growth, confocal laser microscopy in vivo was performed by re-laparotomy. Images of non-malignant and malignant tissue were characterized in terms of specific signal pattern. No fluorescent dye was used. Correlations to findings in conventional histology were systematically recorded and described. Potential tissue damage was examined by conventional histology., Results: All animals survived the operative procedure and could be evaluated 7 days following surgery. No unexpected death occurred after surgery. Non-malignant colon is defined by small cycles of the microvilli of the colon. There is repetitive deregulated structure in colon carcinoma. Peritoneal carcinomatosis showed the same structural pattern as in primary colon carcinoma. In all examined cases, it was possible to differentiate between peritoneal carcinomatosis spots and non-malignant peritoneum. The CLM device did not cause any tissue damage., Conclusions: The CLM camera device reported here is feasible to identify peritoneal carcinomatosis spots, assign these spots to the primary tumor, as well as distinguish between non-malignant and malignant tissue in without using any fluorescent dye.
- Published
- 2019
- Full Text
- View/download PDF
17. Analysis of laparoscopic laser liver resection in standardized porcine model.
- Author
-
Ellebrecht DB, Theisen-Kunde D, Kuempers C, Keck T, Kleemann M, and Wolken H
- Subjects
- Animals, Swine, Carcinoma, Hepatocellular surgery, Hepatectomy methods, Laparoscopy methods, Laser Therapy methods, Liver Neoplasms, Experimental surgery
- Abstract
Background: Hepatocellular carcinoma is a highly prevalent and lethal primary neoplasia of the liver and metastases of other malignancies affect most frequently the liver. Minimally invasive surgical approach for liver resections is advancing. Dissection of liver parenchyma by laparoscopic technique remains challenging and new technologies are in need. Therefore, we asked whether it is feasible to dissect liver tissue comparably in terms of speed and hemostasis with a non-contact 1.9-µm cw-laser device and whether there are differences in the postoperative healing process compared to a gold standard device (ultrasound aspirator) in an experimental model., Methods: Laparoscopic laser and ultrasound aspirator standardized partial liver resections were performed in seven pigs. Resection time, hemostasis time, and blood loss were evaluated. After at least 10 days, representative specimen of the resection areas was collected via re-laparoscopy and biopsy and side effects like hematoma, abscess, or bilioma were noted. Histologically, coagulation necrosis margin, granulation tissue zone, tissue fibrosis, and giant cell count were analyzed., Results: Laparoscopic laser liver resection was three times faster compared to the laparoscopic ultrasound aspirator. Blood loss was equal in both groups. No side effects like hematoma or bilioma occurred. Histologically, specimen showed the same expansion of coagulation necrosis zone and granulation tissue. Fibrotic scar could be determined in three cases in both groups, respectively. However, giant cell count was significant higher in the laser resection group., Conclusions: The 1.9-µm cw-laser device enables a safe and fast liver resection in an experimental pig model compared to a gold standard (ultrasound aspirator) laparoscopic liver resection method. Wound healing is not interfered by laser liver resection.
- Published
- 2018
- Full Text
- View/download PDF
18. An Unexpected Endobronchial Mass Appearing During Bronchoscopy.
- Author
-
Salzer HJF, Kuempers C, Pasternack H, Heyckendorf J, Bialek R, Palade E, Hundack L, Kalsdorf B, and Lange C
- Subjects
- Aspergillus isolation & purification, Bronchi microbiology, Diagnosis, Differential, Humans, Male, Middle Aged, Radiography, Thoracic, Tomography, X-Ray Computed, Bronchi diagnostic imaging, Bronchoscopy methods, Pulmonary Aspergillosis diagnosis
- Abstract
A 60-year-old man was admitted to the hospital with productive cough and yellowish sputum, severe fatigue, and weight loss of 4 kg over the past month; furthermore, he reported a slowly progressive shortness of breath on exertion over the past 6 months. Before admission, he received ampicillin/sulbactam (750 mg) orally twice daily for 7 days without significant clinical improvement., (Copyright © 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
19. Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.
- Author
-
Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, and Perner S
- Abstract
Gleason grading is the best independent predictor for prostate cancer (PCa) progression. Recently, a new PCa grading system has been introduced by the International Society of Urological Pathology (ISUP) and is recommended by the World Health Organization (WHO). Following studies observed more accurate and simplified grade stratification of the new system. Aim of this study was to compare the prognostic value of the new grade groups compared to the former Gleason Grading and to determine whether re-definition of Gleason Pattern 4 might reduce upgrading from prostate biopsy to radical prostatectomy (RP) specimen. A cohort of men undergoing RP from 2002 to 2015 at the Hospital of Goeppingen (Goeppingen, Germany) was used for this study. In total, 339 pre-operative prostatic biopsies and corresponding RP specimens, as well as additional 203 RP specimens were re-reviewed for Grade Groups according to the ISUP. Biochemical recurrence-free survival (BFS) after surgery was used as endpoint to analyze prognostic significance. Other clinicopathological data included TNM-stage and pre-operative PSA level. Kaplan-Meier analysis revealed risk stratification of patients based on both former Gleason Grading and ISUP Grade Groups, and was statistically significant using the log-rank test ( p < 0.001). Both grading systems significantly correlated with TNM-stage and pre-operative PSA level ( p < 0.001). Higher tumor grade in RP specimen compared to corresponding pre-operative biopsy was observed in 44 and 34.5% of cases considering former Gleason Grading and ISUP Grade Groups, respectively. Both, former Gleason Grading and ISUP Grade Groups predict survival when applied on tumors in prostatic biopsies as well as RP specimens. This is the first validation study on a large representative German community-based cohort to compare the former Gleason Grading with the recently introduced ISUP Grade Groups. Our data indicate that the ISUP Grade Groups do not improve predictive value of PCa grading and might be less sensitive in deciphering tumors with 3 + 4 and 4 + 3 pattern on RP specimen. However, the Grade Group system results less frequently in an upgrading from biopsy to the corresponding RP specimens, indicating a lower risk to miss potentially aggressive tumors not represented on biopsies.
- Published
- 2017
- Full Text
- View/download PDF
20. Dysregulation of microRNAs in angioimmunoblastic T-cell lymphoma.
- Author
-
Reddemann K, Gola D, Schillert A, Knief J, Kuempers C, Ribbat-Idel J, Ber S, Schemme J, Bernard V, Gebauer N, Feller AC, and Thorns C
- Subjects
- Adult, Aged, Aged, 80 and over, Cell Line, Tumor, Female, Humans, Lymph Nodes pathology, Lymphadenitis pathology, Lymphoma, T-Cell, Peripheral pathology, Male, MicroRNAs genetics, Middle Aged, Gene Expression Regulation, Neoplastic, Lymphadenitis genetics, Lymphoma, T-Cell, Peripheral genetics, MicroRNAs biosynthesis
- Abstract
Background: Angioimmunoblastic T-cell lymphomas (AITLs) are the second most frequent peripheral T-cell lymphomas in humans worldwide and histomorphologically well characterized. MicroRNAs are a group of small non-coding RNAs that can negatively regulate gene expression on a posttranscriptional level. Their dysregulation has been shown to be of importance in numerous tumour entities., Materials and Methods: As a first step towards understanding the possible influence of microRNA-dysregulation in AITL, we analyzed the expression signatures of 760 microRNAs in 30 nodal AITLs in comparison to reactive lymphadenitis with T-zone hyperplasia., Results: We found miR-34a, miR-146a and miR-193b to be up-regulated, as well as miR-140-3p, let-7g, miR-30b and miR-664 to be down-regulated in AITL to a significant level., Conclusion: The microRNA-signatures of AITL reveal some overlap to autoimmune diseases, virus-triggered lymphomas and angiogenic factors that, coupled with future studies, will potentially provide better understanding of this disease., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.